TuHURA Biosciences (NASDAQ:HURA) Stock Falls 2.1% - Here's Why

Key Points

• TuHURA Biosciences shares fell 2.1% to $1.87 in mid-day trading, with volume about 63% above its daily average.
• Analyst sentiment remains mixed but leans positive: five analysts rate the stock a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and a $9.00 average price target.
• The clinical-stage biotech reported a quarterly loss of $0.14 per share, narrowly beating the $0.15 consensus estimate; its lead program, IFx-2, is an investigational immunotherapy and cancer vaccine candidate.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report)'s share price dropped 2.1% during mid-day trading on Monday. The company traded as low as $1.85 and last traded at $1.87. Approximately 334,271 shares traded hands during mid-day trading, an increase of 63% from the average daily volume of 205,660 shares. The stock had previously closed at $1.91.

Analysts Set New Price Targets

A number of research firms have weighed in on HURA. Citizens Jmp restated a "market outperform" rating and set a $9.00 price objective on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Weiss Ratings reiterated a "sell (e+)" rating on shares of TuHURA Biosciences in a research note on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, TuHURA Biosciences currently has an average rating of "Moderate Buy" and a consensus price target of $9.00.

TuHURA Biosciences Trading Down 2.1%

The firm has a market cap of $119.18 million, a P/E ratio of -3.46 and a beta of -0.21. The stock has a fifty day simple moving average of $2.12 and a 200 day simple moving average of $2.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. On average, research analysts expect that TuHURA Biosciences, Inc. will post -0.55 earnings per share for the current fiscal year.

Institutional Trading of TuHURA Biosciences

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of TuHURA Biosciences during the second quarter valued at approximately $1,615,000. Bank of New York Mellon Corp purchased a new stake in TuHURA Biosciences in the second quarter worth approximately $285,000. Apollon Wealth Management LLC grew its position in TuHURA Biosciences by 17.7% in the 1st quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company's stock worth $283,000 after purchasing an additional 23,717 shares during the period. Cetera Investment Advisers bought a new stake in TuHURA Biosciences in the 1st quarter worth approximately $251,000. Finally, WealthShield Partners LLC purchased a new stake in TuHURA Biosciences during the 2nd quarter valued at $214,000. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc NASDAQ: HURA is a clinical-stage biotechnology company focused on developing therapies designed to overcome immune suppression in the tumor microenvironment and improve responses to cancer treatment. The company's research is centered on immuno-oncology approaches intended to stimulate both innate and adaptive immune responses against tumors.

TuHURA's lead program, IFx-2, is an investigational intratumoral immunotherapy and cancer vaccine candidate designed to reprogram the tumor environment and promote an immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.